Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions

by Bashir Al Hussein Al Awamlh, Neal Patel, Xiaoyue Ma, Adam Calaway, Adam Calaway, Lee Ponsky, Lee Ponsky, Jim C. Hu, Jonathan E. Shoag, Jonathan E. Shoag, Jonathan E. Shoag
Published 2021-05-01

Changes in Urologic Operative Practice at the Beginning of the COVID-19 Pandemic in a Large, National Cohort

by Patrick Lewicki, Camilo Arenas-Gallo, Spyridon P. Basourakos, Nahid Punjani, Siv Venkat, Douglas S. Scherr, Jim C. Hu, Jonathan E. Shoag, Jonathan E. Shoag
Published 2021-05-01

Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer

by Spyridon P. Basourakos, Michael Tzeng, Patrick J. Lewicki, Krishnan Patel, Bashir Al Hussein Al Awamlh, Siv Venkat, Jonathan E. Shoag, Jonathan E. Shoag, Michael A. Gorin, Michael A. Gorin, Christopher E. Barbieri, Jim C. Hu
Published 2021-05-01

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma

by Albert Jang, Jake N. Lichterman, Jeffrey Y. Zhong, Jonathan E. Shoag, Jorge A. Garcia, Tian Zhang, Pedro C. Barata
Published 2023-12-01

Data on the quality and methods of studies reporting healthcare costs of post-prostate biopsy sepsis

by Mark N. Alshak, Michael D. Gross, Jonathan E. Shoag, Aaron A. Laviana, Michael A. Gorin, Art Sedrakyan, Jim C. Hu
Published 2019-08-01

Reply to Tommy Jiang, Sriram V. Eleswarapu, and Vadim Osadchiy’s Letter to the Editor re: Patrick Lewicki, Spyridon P. Basourakos, Bashir Al Hussein Al Awamlh, et al. Estimating th...

by Patrick Lewicki, Spyridon P. Basourakos, Bashir Al Hussein Al Awamlh, Xian Wu, Jim C. Hu, Peter N. Schlegel, Jonathan E. Shoag
Published 2021-07-01

Estimating the Impact of COVID-19 on Urology: Data from a Large Nationwide Cohort

by Patrick Lewicki, Spyridon P. Basourakos, Bashir Al Hussein Al Awamlh, Xian Wu, Jim C. Hu, Peter N. Schlegel, Jonathan E. Shoag
Published 2021-03-01

Treatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study

by Nagaraju Sarabu, Weichuan Dong, Al W. Ray, Austin Fernstrum, Megan Prunty, Lee E. Ponsky, Jonathan E. Shoag, Vahakn B. Shahinian, Krista L. Lentine, Siran M. Koroukian
Published 2023-04-01

Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions

by Samprit Banerjee, Michael D Gross, Bashir Al Hussein Al Awamlh, Jonathan E Shoag, Elizabeth Mauer, Daniel J Margolis, Juan M Mosquera, Ann S Hamilton, Maria J Schumura, Jim C Hu
Published 2019-08-01

Protocol of a multicentre randomised controlled trial assessing transperineal prostate biopsy to reduce infectiouscomplications

by Jonathan E Shoag, Andrew Vickers, Jim Hu, Gerald Wang, David A Green, Tenny R Zhang, Alec Zhu, Mohamad Ezzeddine Allaf, Behfar Ehdaie, Anthony Schaeffer, Christian Pavlovich, Ashley E Ross, Serge Ginzburg, Jeffrey S Montgomery, Arvin George, John N Graham, Benjamin T Ristau, Andres Correa, Keith J Kowalczyk, EM Schaeffer
Published 2023-05-01

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes

by Deli Liu, Jonathan E. Shoag, Daniel Poliak, Ramy S. Goueli, Vaishali Ravikumar, David Redmond, Aram Vosoughi, Jacqueline Fontugne, Heng Pan, Daniel Lee, Domonique Thomas, Keyan Salari, Zongwei Wang, Alessandro Romanel, Alexis Te, Richard Lee, Bilal Chughtai, Aria F. Olumi, Juan Miguel Mosquera, Francesca Demichelis, Olivier Elemento, Mark A. Rubin, Andrea Sboner, Christopher E. Barbieri
Published 2020-04-01